Related Experiment Video
Updated: Feb 12, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Anemia Associated with Worse Outcome in Diffuse Large B-Cell Lymphoma Patients: A Single-Center Retrospective Study
Kenji Matsumoto1, Shin Fujisawa2, Taiki Ando2
1Yokohama City University Faculty of Medicine, Department of Hematology and Clinical Immunology, Yokohama, Japan
Insights
Anemia, indicated by low hemoglobin (Hb) levels (<10 g/dL), is a significant independent prognostic marker for poor outcomes in diffuse large B-cell lymphoma (DLBCL) patients. This finding aids in risk stratification for DLBCL treatment.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Diffuse large B-cell lymphoma (DLBCL) is a common non-Hodgkin lymphoma.
- Identifying reliable prognostic biomarkers is crucial for effective patient management and risk stratification.
- Previous studies have reported various prognostic factors in DLBCL.
Purpose of the Study:
- To investigate the prognostic value of hemoglobin (Hb) levels in patients diagnosed with DLBCL.
- To determine if Hb level can serve as an independent prognostic marker for disease outcome.
Main Methods:
- A retrospective study was conducted on 185 DLBCL patients treated between 2004 and 2014.
- Patients received standard therapy including rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.
- Disease outcome, progression-free survival (PFS), and overall survival were evaluated along with clinical and laboratory factors.
Main Results:
- Univariate analysis identified factors associated with worse PFS, including ECOG performance status ≥2, Ann Arbor stage III/IV, anemia (Hb <10 g/dL), and low serum albumin (<3.5 g/dL).
- Multivariate analysis confirmed anemia (Hb <10 g/dL) and Ann Arbor stage III/IV as independent prognostic factors, irrespective of the International Prognostic Index.
- Anemia showed a hazard ratio of 2.4 (p=0.04) in multivariate analysis.
Conclusions:
- Anemia, defined by Hb levels below 10 g/dL, is an independent prognostic marker associated with poorer outcomes in DLBCL patients.
- Hemoglobin level represents an accessible and valuable biomarker for risk stratification in DLBCL patient management.
- These findings support the integration of Hb level assessment into routine prognostic evaluation for DLBCL.
Objective:
Useful prognostic biomarkers for diffuse large B-cell lymphoma (DLBCL) patients have been reported. To determine the prognostic value of hemoglobin (Hb) level in DLBCL patients, we performed a retrospective study.
Materials And Methods:
We evaluated disease outcome, progression-free survival (PFS), overall survival as the endpoint, and clinical and laboratory factors affecting the outcome of 185 DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy during 2004-2014.
Results:
The study group included 121 men and 64 women with a median age of 66 years minimum-maximum: 21-83 years. In univariate analysis, factors independently associated with worse PFS were Eastern Cooperative Oncology Group performance status ≥2, Ann Arbor stage III or IV, anemia with Hb levels of <10 g/dL, and serum albumin of <3.5 g/dL. In multivariate analysis, anemia with Hb levels of <10 g/dL and Ann Arbor stage III or IV were found to be international index-independent prognostic factors (hazard ratio: 2.4; p=0.04).
Conclusion:
Anemia is an independent prognostic marker of poor outcome in DLBCL patients. Hb can be an easily available prognostic marker for risk stratification in these patients.
Related Concept Videos
Patient-centered Care
Diffusion
Diffusion
Lattice Centering and Coordination Number
Types of Unit Cells
Imagine taking a large number of identical...
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Predicting Reaction Outcomes

